Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Share-based Compensation (2016 - 2025)

United Therapeutics' Share-based Compensation history spans 17 years, with the latest figure at $39.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 44.44% year-over-year to $39.0 million; the TTM value through Dec 2025 reached $147.7 million, up 2.57%, while the annual FY2025 figure was $147.7 million, 2.57% up from the prior year.
  • Share-based Compensation for Q4 2025 was $39.0 million at United Therapeutics, roughly flat from $39.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $65.5 million in Q2 2022 and bottomed at -$21.1 million in Q1 2022.
  • The 5-year median for Share-based Compensation is $30.4 million (2021), against an average of $28.8 million.
  • The largest annual shift saw Share-based Compensation crashed 152.62% in 2022 before it skyrocketed 979.17% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $44.7 million in 2021, then surged by 44.97% to $64.8 million in 2022, then plummeted by 74.38% to $16.6 million in 2023, then surged by 62.65% to $27.0 million in 2024, then skyrocketed by 44.44% to $39.0 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Share-based Compensation are $39.0 million (Q4 2025), $39.1 million (Q3 2025), and $37.8 million (Q2 2025).